Skip to main content

Table 4 Treatment-emergent AEs, overall and by preferred term (≥2.5 % with either treatment) (safety set)

From: Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)

  IND/GLY (N = 193) Placebo (N = 188)
Events, n Patients, n (%) Events, n Patients, n (%)
All TEAEs 73 44 (22.8) 48 43 (22.9)
 Cough 8 8 (4.1) 3 3 (1.6)
 Nasopharyngitis 7 7 (3.6) 8 8 (4.3)
 Headache 7 6 (3.1) 3 3 (1.6)
Suspected related TEAEs 12 11 (5.7) 4 4 (2.1)
 Cough 5 5 (2.6) 1 1 (0.5)
Serious TEAEs 4 4 (2.1) 2 2 (1.1)
 Deaths 1 1 (0.5) 0 0
 Suspected related serious TEAE 0 0 0 0
  1. TEAE treatment-emergent adverse event